Pfizer (PFE) Insider James Quincey Buys $39K of Stock
James Quincey bought 1,595 shares of Pfizer Inc. on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
James Quincey bought 1,595 shares of Pfizer Inc. ($PFE) at an average price of $24.29, worth about $38,742.55, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PFE is down 2.4% after 1 week, up 3.4% after 1 month and up 23.9% to date (from the $23.87 close on Jun 26, 2026).
PFE
Pfizer Inc.
Key Points
- On June 26, 2026, James Quincey bought 1,595 shares of Pfizer Inc. for $38,742.55, with the stock priced at $24.29 at the time of the purchase.
- Pfizer's stock is currently trading at $24.08, down from a previous close of $27.66, indicating a challenging market environment.
- The company's most recent earnings report showed $63.7 billion in revenue and a net margin of 6.8%, with the next earnings date set for November 3, 2026.
Get $PFE trade alerts by text
We text you when insiders, Congress or big funds trade $PFE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Pfizer Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Pfizer Inc.
James Quincey purchased 1,595 shares of Pfizer Inc. (NYSE: PFE) on June 26, 2026, for a total value of $38,742.55. The shares were bought at a price of $24.29 each. This transaction adds to the recent trend of insider buying at Pfizer, reflecting confidence in the company despite current market conditions.
Other Insider Activity
On the same day, several other insiders also made purchases. Shantanu Narayen bought 2,059 shares at $24.29, totaling $50,013.11. Cyrus Taraporevala acquired 1,544 shares, also at $24.29, valued at $37,503.76. Joseph Echevarria purchased 1,904 shares for $46,248.16. This collective buying from multiple insiders may indicate a positive outlook for Pfizer.
How Pfizer Inc. Stock Has Traded
Pfizer's shares are currently trading at $24.08, which is lower than the previous close of $27.66. The stock has a 52-week low of $23.58 and a high of $29.21. This recent insider buying comes as the stock trades below its 50-day moving average of $26.69, suggesting potential value for investors looking at the company.
Recent Earnings
In its latest earnings report, Pfizer reported revenue of approximately $63.7 billion, reflecting a revenue growth of 2.6%. The company's net margin stands at 6.8%, and its return on equity is 5%. The next earnings report is scheduled for November 3, 2026, which investors will be watching closely.
What Pfizer Inc. Does
Pfizer Inc. is a major player in the healthcare sector, focusing on the discovery and manufacturing of biopharmaceutical products. Its diverse portfolio includes treatments for various diseases, vaccines, and oncology products. The recent insider transactions suggest that executives believe in the company's future potential.
What's Ahead for Pfizer Inc.
With the next earnings report approaching on November 3, 2026, investors will be eager to see how Pfizer performs in the current market. The recent insider buying may also influence market perceptions as these executives continue to show confidence in the company's direction.
Related Filing Alerts
Source: James Quincey's Form 4 filing on $PFE (Jun 26, 2026). Find the original filing: PFE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts